# M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)

> **NCT03840915** · PHASE1,PHASE2 · COMPLETED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 70 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed
- **DRUG:** Nab-paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Docetaxel
- **DRUG:** M7824
- **DRUG:** Carboplatin
- **DRUG:** Carboplatin
- **DRUG:** Bintrafusp alfa
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03840915
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-02
- **Primary completion:** 2022-07-29
- **Final completion:** 2022-07-29
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2023-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03840915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03840915, "M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03840915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*